Blackford Analysis Engages with Optos on Ophthalmology Application

Edinburgh, UK – November 3, 2015 - Blackford Analysis, a provider of software products that accelerate comparison of medical images, today announced it has secured a second consulting engagement with Optos, a global leader in ultra-widefield retinal imaging technology.

Following a successful six-week pilot project that looked into the feasibility of using Blackford’s technology to enhance Optos’ retinal reviewing capabilities, the companies have begun an extended project to implement time saving solutions within Optos’ software.

“We already use similar techniques developed internally, but it became apparent from the pilot project that Blackford can significantly enhance the results and on a rapid timescale” said Derek Swan, Vice President of Research, Optos. “We are looking forward to working with the team at Blackford again as we move towards a production-ready solution.”

Blackford’s primary business is in delivering medical imaging solutions in the radiology sector, and the Optos project builds on that platform, albeit in a different medical field.

“As we already develop solutions for radiology, our core technology is well-suited to the rigorous demands of other areas of medical imaging across the healthcare enterprise, including areas like ophthalmology and orthopedics,” said Blackford CEO, Ben Panter. “Our consulting division is more than capable of the kinds of bespoke development required to deliver solutions in a broad range of imaging applications.”

About Blackford Analysis
Blackford Analysis is a developer of software solutions for the medical sector. The company develops software designed to accelerate medical image comparison – saving time and increasing clinician capacity. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by Archangel Informal Investment, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com

About Optos Plc
Optos has the vision to be The Retina Company and to be recognised as a leading provider of devices and solutions to eyecare professionals for improved patient care. Optos’ core devices produce ultra-widefield, high resolution digital images (optomap®) of approximately 82% of the retina, something no other device is capable of doing in a single image capture.   Optos also offers optical coherence tomography ("OCT") devices which delivers an image that shows a three dimensional, cross-sectional view of the retina in the central area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect. For more information please visit our website www.optos.com

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.